Table 2 Details of subgroup analysis

OS

 Region

Asia

5

2.33 [1.33, 4.07]

80

Europe

3

2.62 [1.63, 4.22]

68

Africa

1

2.01 [1.01, 4.00]

-

 Sample size

 ≥ 250

5

2.05 [1.24, 3.39]

76

< 250

4

3.21 [2.80, 3.67]

0

 Stage

I-IV

4

2.14 [1.15, 3.96]

81

III-IV

4

2.67 [1.94, 3.68]

56

 Treatment

Surgery

4

2.24 [1.05, 4.76]

79

Chemotherapy

2

2.02 [1.41, 2.91]

0

Surgery + chemotherapy

3

3.12 [2.53, 3.84]

13

 Adjusted data

Yes

7

2.66 [1.97, 3.57]

53

No

2

1.55 [0.80, 3.03]

64

 Cut-off

> 700

4

1.73 [1.13, 2.64]

64

< 700

5

2.88 [2.07, 4.02]

46

 Method of cut-off

ROC curve

5

2.16 [1.15, 4.08]

93

X-tile

2

3.37 [1.07, 10.63]

79

Literature

2

2.02 [1.41, 2.91]

0

 NOS score

8–9

6

2.66 [1.95, 3.63]

61

6–7

3

1.51 [0.90, 2.52]

34

DFS

 Region

Asia

6

2.73 [1.55, 4.82]

87

Europe

3

2.10 [0.95, 4.62]

52

Africa

1

2.68 [1.17, 6.14]

-

 Sample size

≥ 250

5

2.13 [1.28, 3.55]

84

< 250

5

2.85 [2.08, 3.89]

0

 Stage

I-IV

4

2.69 [1.18, 6.15]

89

III-IV

3

2.22 [1.21, 4.07]

75

 Treatment

Surgery

5

2.98 [1.32, 6.76]

86

Chemotherapy

3

2.19 [1.22, 3.95]

75

Surgery + chemotherapy

2

2.62 [1.64, 4.18]

0

 Adjusted data

Yes

8

2.71 [1.82, 4.05]

65

No

2

1.98 [0.65, 6.01]

89

 Cut-off

> 700

6

1.83 [1.27, 2.64]

70

< 700

4

3.65 [2.33, 5.73]

34

 Method of cut-off

ROC curve

5

2.04 [1.26, 3.31]

75

X-tile

2

4.37 [1.59, 11.97]

75

Literature

2

2.48 [0.55, 11.22]

71

 NOS score

8–9

6

2.89 [1.70, 4.92]

74

6–7

4

2.13 [1.14, 3.99]

81